---

發稿單位：NIH
發稿時間：2021 Apr 20.
撰 稿 者：NIH 眾學者, 網址裡面有列.
原文連結：https://pubmed.ncbi.nlm.nih.gov/33864917/

Positive impact of oral hydroxychloroquine and povidone-iodine throat spray
for COVID-19 prophylaxis: An open-label randomized trial

Abstract
Background: We examined whether existing licensed pharmacotherapies could
reduce the spread of coronavirus disease 2019 (COVID-19).

Methods: An open-label parallel randomized controlled trial was performed
among healthy migrant workers quarantined in a large multi-storey dormitory
in Singapore. Forty clusters (each defined as individual floors of the
dormitory) were randomly assigned to receive a 42-day prophylaxis regimen of
either oral hydroxychloroquine (400 mg once, followed by 200 mg/day), oral
ivermectin (12 mg once), povidone-iodine throat spray (3 times/day, 270 μ
g/day), oral zinc (80 mg/day)/vitamin C (500 mg/day) combination, or oral
vitamin C, 500 mg/day. The primary outcome was laboratory evidence of
SARS-CoV-2 infection as shown by either: (1) a positive serologic test for
SARS-CoV-2 antibody on day 42, or (2) a positive PCR test for SARS-CoV-2 at
any time between baseline and day 42.

Results: A total of 3037 asymptomatic participants (mean age, 33.0 years; all
men) who were seronegative to SARS-CoV-2 at baseline were included in the
primary analysis. Follow-up was nearly complete (99.6%). Compared with
vitamin C, significant absolute risk reductions (%, 98.75% confidence
interval) were observed for oral hydroxychloroquine (21%, 2-42%) and
povidone-iodine throat spray (24%, 7-39%). No statistically significant
differences were observed with oral zinc/vitamin C combination (23%, -5 to
+41%) and ivermectin (5%, -10 to +22%). Interruptions due to side effects
were highest among participants who received zinc/vitamin C combination
(6.9%), followed by vitamin C (4.7%), povidone-iodine (2.0%), and
hydroxychloroquine (0.7%).

Conclusions: Chemoprophylaxis with either oral hydroxychloroquine or
povidone-iodine throat spray was superior to oral vitamin C in reducing
SARS-CoV-2 infection in young and healthy men.

我直接講重點,
這份報告是去年中針對 3000 多人做實驗組與對照組的比對實驗,
今年 2021 Apr 20 才發表,
整整做了一年的實驗,
所以是蠻可靠的實驗,

結論是 HCQ 在年輕人和健康人身上減少感染武漢肺炎的效果優於維生素 C 的治療.

其餘報告內容可以看網址裡面的相關連結,
很多, 太多了,
有興趣的可以一一去看.

________________________

感想:

NIH 都正式發表了,
我記得台灣還將 HCQ 移出用藥指南,
有寄信請台灣的衛福部要求進行更正,

之前台灣去年有備大量的 HCQ,
但後來因為移出用藥指南後,
變成很大的庫存,

得到的消息是,
這些庫存有發到各藥局去銷庫存,
我是希望衛福部可以比照口罩的方式,
用健保卡限制分發,
讓每個人都能拿到這樣比較好,
以上是個人觀點.

--
--
※ 發信站: 批踢踢實業坊(ptt.cc), 來自: 101.10.58.35 (臺灣)
※ 文章代碼(AID): #1WhaI8wN (nCoV2019)
※ 文章網址: https://www.ptt.cc/bbs/nCoV2019/M.1622033544.A.E97.html